Skip to main content
Clinical Trials/NCT04338386
NCT04338386Not yet recruitingNot Applicable

Detection and Pathogenesis of Novel Protein F

Wuhan Asia Heart Hospital0 sites100 target enrollmentStarted: April 15, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
100
Primary Endpoint
Concentration of plasma protein F content

Study Overview

Brief Summary

From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.

Detailed Description

Protein F screening was performed on anticoagulant blood plasma with heparin Lithium or blood serum by in-house turbidimetric method in Automatic biochemical analyzer.

All patients were followed-up for 3 years by telephones, routine appointment out-patient clinic or returning visit.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Testing total protein and albumin
  • Testing routine blood test

Exclusion Criteria

  • high triglycerides (TG>5.00 mmol/L)
  • hyperbilirubinemia (TBIL>170 mmol/L)
  • fat emulsion used in past 3 days
  • patients with hemolytic disease
  • pregnant and lactating women

Outcomes

Primary Outcomes

Concentration of plasma protein F content

Time Frame: six month

the protein F content was measured by turbidimetric assay in automatic biochemical analyzer

Secondary Outcomes

  • Number of Participants with Multiple myeloma(3 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials